Adrian Newman‐Tancredi

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

Mark J. Millan, Alain P. Gobert, F. Lejeune et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 509 citations · Full text

Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes

Mark J. Millan, Lisa Maiofiss, Didier Cussac et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 477 citations · Full text

Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat

Alain P. Gobert, Jean‐Michel Rivet, F. Lejeune et al. · Synapse · 2000 · 335 citations

Psychopharmacology, Antagonist Mdl100,907, Social Sciences +19

Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety

Agnès L. Auclair, J.-C. Martel, M.B. Assié et al. · Neuropharmacology · 2013 · 259 citations · Full text

Psychotropic Medication, Psychopharmacology, Pharmacotherapy +17

Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a []GTPγS binding study

Adrian Newman‐Tancredi, Samantha Gavaudan, Caroline Conte et al. · European Journal of Pharmacology · 1998 · 226 citations

Molecular Pharmacology, Antagonist Actions, Antipsychotic Agents +8